Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats

American Journal of Respiratory and Critical Care Medicine

Volumn 183, Issue 10, 2011, Pages 1402-1410

  Bogaard, Harm J ^a,b   Mizuno, Shiro ^a   Al Hussaini, Ayser A ^a   Toldo, Stefano ^a   Abbate, Antonio ^a   Kraskauskas, Donatas ^a   Kasper, Michael ^c   Natarajan, Ramesh ^a   Voelkel, Norbert F ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Histone deacytelase inhibitor; Pulmonary artery banding; Pulmonary hypertension; Right ventricular hypertrophy

Indexed keywords

ANGIOPOIETIN 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; TRICHOSTATIN A; VALPROIC ACID; VASCULAR ENDOTHELIAL GROWTH INHIBITOR; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY RAREFACTION; CELL DEATH; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFECT; ECHOCARDIOGRAPHY; ENZYME INHIBITION; ENZYME REPRESSION; FIBROBLAST; FIBROSIS; GENE EXPRESSION; GENE SILENCING; HEART HEMODYNAMICS; HEART LEFT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE OVERLOAD; HEART VENTRICLE REMODELING; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ARTERY BANDING; MALE; MICROVASCULAR ENDOTHELIAL CELL; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANGIOPOIETIN-1; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY, DOPPLER; HEART VENTRICLES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; LIGATION; MALE; NITRIC OXIDE SYNTHASE; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; VALPROIC ACID; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR SURGICAL PROCEDURES; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR REMODELING;

EID: 79956200230     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201007-1106OC     Document Type: Article

References (32)

1. Bush EW, McKinsey TA. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors. Circ Res 2010;106:272-284.
2. Kee HJ, Sohn IS, Nam KI, Park JE, Qian YR, Yin Z, Ahn Y, Jeong MH, Bang YJ, Kim N, et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 2006;113:51-59. (Pubitemid 43958488)
3. Kong Y, Tannous P, Lu G, Berenji K, Rothermel BA, Olson EN, Hill JA. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 2006;113:2579-2588. (Pubitemid 43948006)
4. Trivedi CM, Luo Y, Yin Z, Zhang M, Zhu W, Wang T, Floss T, Goettlicher M, Noppinger PR, Wurst W, et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med 2007;13:324-331. (Pubitemid 46376684)
5. Granger A, Abdullah I, Huebner F, Stout A, Wang T, Huebner T, Epstein JA, Gruber PJ. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J 2008;22:3549-3560.
6. Daosukho C, Chen Y, Noel T, Sompol P, Nithipongvanitch R, Velez JM, Oberley TD, St Clair DK. Phenylbutyrate, a histone deacetylase inhibitor, protects against adriamycin-induced cardiac injury. Free Radic Biol Med 2007;42:1818-1825. (Pubitemid 46754756)
7. Ellis L, Hammers H, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 2009;280:145-153.
8. Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 2004;101:18030-18035. (Pubitemid 40054069)
9. Emanuele S, Lauricella M, Tesoriere G. Histone deacetylase inhibitors: apoptotic effects and clinical implications. Int J Oncol 2008;33:637-646. (Review).
10. Bogaard HJ, Abe K, Vonk-Noordegraaf A, Voelkel NF. The right ventricle under pressure; cellular and molecular mechanisms of right heart failure in pulmonary hypertension. Chest 2009;135:794-804.
11. Kreymborg K, Uchida S, Gellert P, Schneider A, Boettger T, Voswinckel R, Wietelmann A, Szibor M, Weissmann N, Ghofrani AH, et al. Identification of right heart-enriched genes in a murine model of chronic outflow tract obstruction. J Mol Cell Cardiol 2010;49:598-605.
12. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann InternMed 1991;115:343-349.
13. Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, Arbustini E, Recusani F, Tavazzi L. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001;37:183-188. (Pubitemid 32051736)
14. Bogaard HJ, Natarajan R,Mizuno S, Abbate A, Chang P, Chau V, Hoke N, Kraskauskas D, Kasper M, Salloum F, et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med 2010;182:652-660.
15. Bogaard HJ, Natarajan R, Kraskauskas D, Smithson L, Voelkel NF. Suppression of histone deacetylases worsens right ventricular hypertrophy and induces failure after pulmonary artery banding in rats. Am J Respir Crit Care Med 2009;179:A4142.
16. Bogaard HJ, Natarajan R, Henderson SC, Long CS, Kraskauskas D, Smithson L, Ockaili R, McCord JM, Voelkel NF. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 2009;120:1951-1960.
17. Faber MJ, Dalinghaus M, Lankhuizen IM, Bezstarosti K, Verhoeven AJ, Duncker DJ, Helbing WA, Lamers JM. Time dependent changes in cytoplasmic proteins of the right ventricle during prolonged pressure overload. J Mol Cell Cardiol 2007;43:197-209. (Pubitemid 47069377)
18. Faber MJ, Dalinghaus M, Lankhuizen IM, Steendijk P, Hop WC, Schoemaker RG, Duncker DJ, Lamers JMJ, Helbing WA. Right and left ventricular function after chronic pulmonary artery banding in rats assessed with biventricular pressure-volume loops. Am J Physiol Heart Circ Physiol 2006;291:H1580-H1586. (Pubitemid 44497661)
19. Mizuno S, Bogaard HJ, Voelkel NF, Umeda Y, Kadowaki M, Ameshima S, Miyamori I, Ishizaki T. Hypoxia regulates human lung fibroblast proliferation via p53-dependent and -independent pathways. Respir Res 2009;10:17.
20. Takeda N, Manabe I, Uchino Y, Eguchi K, Matsumoto S, Nishimura S, Shindo T, Sano M, Otsu K, Snider P, et al. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J Clin Invest 2010;120:254-265.
21. Khan R, Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 2006;118:10-24.
22. Weber KT, Janicki S, Shroff JSG, Pick R, Chen RM, Bashey RI. Collagen remodeling of the pressure-overloaded, hypertrophied non-human primate myocardium. Circ Res 1988;62:757-765.
23. Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y, Akazawa H, Tateno K, Kayama Y, Harada M, et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007;446:444-448. (Pubitemid 46474597)
24. Antos CL, McKinsey TA, Dreitz M, Hollingsworth LM, Zhang CL, Schreiber K, Rindt H, Gorczynski RJ, Olson EN. Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J Biol Chem 2003;278:28930-28937. (Pubitemid 36935803)
25. Mommersteeg MT, Brown NA, Prall OW, de Gier-de VC, Harvey RP, Moorman AF, Christoffels VM. Pitx2c and Nkx2-5 are required for the formation and identity of the pulmonary myocardium. Circ Res 2007;101:902-909. (Pubitemid 350287177)
26. Houweling AC, van Borren MM, Moorman AFM, Christoffels VM. Expression and regulation of the atrial natriuretic factor encoding gene Nppa during development and disease. Cardiovasc Res 2005;67:583-593. (Pubitemid 41033354)
27. Fischle W, Wang Y, Allis CD. Histone and chromatin cross-talk. Curr Opin Cell Biol 2003;15:172-183. (Pubitemid 36332192)
28. Backs J, Olson EN. Control of cardiac growth by histone acetylation/ deacetylation. Circ Res 2006;98:15-24. (Pubitemid 43977219)
29. Montgomery RL, Davis CA, Potthoff MJ, Haberland M, Fielitz J, Qi X, Hill JA, Richardson JA, Olson EN. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev 2007;21:1790-1802. (Pubitemid 47076478)
30. Cho YK, Eom GH, Kee HJ, Kim HS, Choi WY, Nam KI, Ma JS, Kook H. Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats. Circ J 2010;74:760-770.
31. Montgomery RL, Potthoff MJ, Haberland M, Qi X, Matsuzaki S, Humphries KM, Richardson JA, Bassel-Duby R, Olson EN. Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest 2008;118:3588-3597.
32. Rai PR, Cool CD, King JA, Stevens T, Burns N, Winn RA, Kasper M, Voelkel NF. The cancer paradigm of severe angioproliferative pulmonary hypertension. Am J Respir Crit Care Med 2008;178:558-564.